University Hospitals Seidman Cancer Center

Artificial intelligence applications in prostate cancer

Atallah Baydoun, Angela Y. Jia, Nicholas G. Zaorsky et al.

2023 · 69 Zit.

External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial

Ashley E. Ross, Jingbin Zhang, Huei–Chung Huang et al.

2024 · 25 Zit.

Meta-analysis of Individual Patient-level Data for a Multimodal Artificial Intelligence Biomarker in High-risk Prostate Cancer: Results from Six NRG/RTOG Phase 3 Randomized Trials

Daniel E. Spratt, Vinnie Y T Liu, Angela Y. Jia et al.

2024 · 9 Zit.

Assessing Algorithmic Fairness With a Multimodal Artificial Intelligence Model in Men of African and Non-African Origin on NRG Oncology Prostate Cancer Phase III Trials

Mack Roach, Jingbin Zhang, Osama Mohamad et al.

2025 · 4 Zit.

NIMG-66. AI-BASED PROGNOSTIC IMAGING BIOMARKERS FOR PRECISION NEUROONCOLOGY AND THE RESPOND CONSORTIUM

Christos Davatzikos, Chaitra Badve, Anahita Fathi Kazerooni et al.

2020 · 3 Zit.

Trial prospector: An automated clinical trials eligibility matching program.

Andrew J. Parchman, Guo‐Qiang Zhang, Patrick Mergler et al.

2013 · 1 Zit.

Unravelling the evolution of medical scientific publishing to hold the promise of science for better patient care

Riccardo Bertolo, Riccardo Campi, Nicholas G. Zaorsky et al.

2024 · 1 Zit.

Post-Prostatectomy Risk Stratification of Biochemical Recurrence Using Transfer Learning-Based Multi-Modal Artificial Intelligence

Atallah Baydoun, Yilun Sun, Angela Y. Jia et al.

2023 · 0 Zit.

Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE.

Charles Thomas Parker, Vinnie YT Liu, Larissa Mendes et al.

2025 · 0 Zit.

Artificial intelligence applications in neuro-oncology

Tyler Slater, Prashant Vempati, Atallah Baydoun

2026 · 0 Zit.